研究单位：[1]Suzhou Suncadia Biopharmaceuticals Co.,Ltd.[2]Fujian Provincial Cancer Hospital Fuzhou,Fujian,China,350000[3]Guangdong Provincial People's Hospital Guangzhou,Guangdong,China,510080[4]Hunan Cancer Hospital Changsha,Hunan,China,410000[5]The Second Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China,330000[6]The First Hospital of JiLin University Changchun,Jlin,China,132000[7]Shandong Cancer Hospital&Institute Jinan,Shandong,China,250000[8]The Second Affiliated Hospital of Air Force Military University Tangdu Hospital Xi'an,Shanxi,China,710000[9]Sichuan Cancer Hospital & Institute Chengdu,Sichuan,China,610000[10]West China Hospital,Sichuan University Chengdu,Sichuan,China,610000[11]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650000[12]National Cancer Center Hospital East Chiba,Japan,277-8577[13]National Cancer Center Hospital Tokyo,Japan,104-0045[14]Seoul National University Hospital Seoul,Korea,Republic of,03080[15]Asan Medical Center Seoul,Korea,Republic of,05505[16]Samsung Medical Center Seoul,Korea,Republic of,06351[17]Chongqing Cancer Hospital Chongqi,Chongqi,China,400000
研究目的：
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
VM29:84 Condition or disease: Advanced Solid Tumors
